Biondvax Pharma's flu vaccine candidate unsuccessful in late-stage study

• Biondvax Pharmaceuticals craters (BVXV -86.7%) after it announced topline data from Phase 3 trial evaluating universal flu vaccine candidate M-001.
• The company reported that the trial failed to achieve both the primary and secondary endpoints. Specifically, M-001 failed to statistically separate from placebo in reduction of flu illness and severity.
• The study's primary safety endpoint was met.
• https://seekingalpha.com/news/3625391-biondvax-pharmas-flu-vaccine-candidate-unsuccessful-in-late-stage-study